Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination
-- NCI will lead the Phase 1 study using Gritstone’s proprietary “off the shelf” vaccine technology for mutant KRAS solid...